TITLE

Melphalan/topotecan

PUB. DATE
November 2017
SOURCE
Reactions Weekly;11/18/2017, Vol. 1678 Issue 1, p119
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses patients with retinoblastoma along with the posterior segment complications during treatment and the use of melphalan and topotecan on the patients.
ACCESSION #
126306669

 

Related Articles

  • Antithymocyte-globulin/busulfan/fludarabine/melphalan.  // Reactions Weekly;1/21/2017, Vol. 1635 Issue 1, p41 

    An abstract of the article "T-cell-replete haploidentical stem cell transplantation is highly efficacious for relapsed and refractory childhood acute leukaemia" by S. Kobayashi and others is presented.

  • FDA Actions.  // CenterWatch Monthly;Sep2015, Vol. 22 Issue 9, p20 

    A chart is presented which lists the regulatory actions taken by the U.S. Food and Drug Administration (FDA) against several drugs including melphalan, inecalcitol and Anisina.

  • Topotecan.  // Reactions Weekly;5/4/2013, Issue 1451, p47 

    The article describes the case of a 37-year-old woman who developed Sweet's syndrome during treatment of recurrent low-malignant potential neoplasm of the ovary with topotecan.

  • Validation of a new integrated prognostic score to predict non-relapse mortality in patients undergoing reduced-intensity conditioning allogeneic hematopoietic cell transplantation. Barba, P; Martino, R; Orti, G; Esquirol, A; Perez-Hoyos, S; Sierra, J; Valcárcel, D // Bone Marrow Transplantation;Oct2015, Vol. 50 Issue 10, p1371 

    The article focuses on a study conducted to estimate a prognostic score for predicting the risk of non-relapse mortality (NRM) in patients treated with allogeneic hematopoietic cell transplantation (allo-HCT). Topics discussed include administration of fludarabine in combination with melphalan;...

  • High-dose chemotherapy and autologous stem cell transplantation with melphalan, etoposide and carboplatin for high-risk osteosarcoma. Hong, C R; Kang, H J; Kim, M S; Ju, H Y; Lee, J W; Kim, H; Kim, H-S; Park, S-H; Park, K D; Park, J D; Shin, H Y; Ahn, H S // Bone Marrow Transplantation;Oct2015, Vol. 50 Issue 10, p1375 

    The article focuses on a study related to chemotherapy and autonomous stem cell transplantation (ASCT) as a treatment of osteosarcoma. Topics discussed include patients undergoing ASCT with melphalan in combination with other drugs; surgical resection of the primary tumor and adjuvant...

  • Extramedullary relapse after accidental head injury in a patient with multiple myeloma. Merz, Maximilian; Schweizer, Leonille; Kentar, Modar; Schneider, Till; Goldschmidt, Hartmut; Hillengass, Jens // Annals of Hematology;Feb2015, Vol. 94 Issue 2, p351 

    The article presents a case study of 53-year-old male with multiple myeloma who was taken to the clinic with a painless lump on his right forehead. Topics discussed include initiation of primary treatment with high-dose melphalan supported with autologous stem cell transplantation (ASCT) and...

  • Combined intravitreal melphalan and intravenous/intra-arterial chemotherapy for retinoblastoma with vitreous seeds. Lee, Ji; Han, Jung; Hahn, Seung; Lyu, Chuhl; Kim, Dong; Lee, Sung // Graefe's Archive of Clinical & Experimental Ophthalmology;Feb2016, Vol. 254 Issue 2, p391 

    Purpose: We aimed to evaluate the therapeutic effect and complications of combined intravitreal melphalan and intravenous/intra-arterial chemotherapy as a primary approach for retinoblastoma with vitreous seeds. Methods: In this retrospective case series, eight eyes from eight retinoblastoma...

  • Melphalan Injection.  // AHFS Consumer Medication Information;Apr2018, p1 

    Melphalan injection is used to treat multiple myeloma (a type of cancer of the bone marrow). Melphalan injection should only be used to treat people who are unable to take melphalan by mouth. Melphalan is in a class of medications called alkylating agents. It works by stopping or slowing the...

  • Predicting the effects of 8C2, a monoclonal anti-topotecan antibody, on plasma and tissue disposition of topotecan. Shah, Dhaval; Balthasar, Joseph // Journal of Pharmacokinetics & Pharmacodynamics;Feb2014, Vol. 41 Issue 1, p55 

    We are investigating an inverse targeting strategy to reduce the dose limiting systemic toxicities resultant from intraperitoneal administration of topotecan, a model chemotherapeutic drug. This approach utilizes systemic co-administration of anti-topotecan antibodies to alter the plasma and...

  • Co-targeting the IGF system and HIF-1 inhibits migration and invasion by (triple-negative) breast cancer cells. Mancini, M; Gariboldi, M B; Taiana, E; Bonzi, M C; Craparotta, I; Pagin, M; Monti, E // British Journal of Cancer;6/10/2014, Vol. 110 Issue 12, p2865 

    Background:Metastatic triple-negative breast cancer is mostly incurable, due to lack of suitable drug targets. The insulin-like growth factor (IGF) system could provide such a target, and IGF-1 receptor (IGF-1R)-directed agents are already available, but seem unable to control all the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics